Gosset Molecular Classification
Transmembrane glycoprotein, Immunoglobulin superfamily, Siglec family, Receptor
Other Names
Siglec-2
Disease Roles
Cluster of Differentiation 22 Overview
CD22 is a transmembrane glycoprotein and member of the Siglec family, primarily expressed on mature B cells and B-cell precursors. It acts as an inhibitory coreceptor for the B-cell receptor (BCR), dampening B-cell activation. It is a validated target for immunotherapies against hematologic malignancies, including CAR-T cells and monoclonal antibodies.
Mechanism of Action
Targeted elimination of CD22-expressing malignant cells through CAR-T cell cytotoxicity or antibody-mediated immune effector mechanisms; Inhibition of BCR signaling.
Biological Functions
Negative regulation of B-cell receptor (BCR) signaling
Modulation of B-cell survival
Inhibits signal transduction
Disease Associations
Cancer
Hematologic malignancies
B-cell acute lymphoblastic leukemia (BCP-ALL)
Safety Considerations
- Off-tumor toxicity
- Antigen escape
- Cytokine release syndrome (CRS) in CAR-T therapy
Interacting Drugs
Anti-CD22 CAR T-cells
Monoclonal antibodies targeting CD22
Trispecific antibodies (CD19/CD20/CD22)
Associated Biomarkers
| Biomarker |
|---|
| CD22 expression level in B cells |
| CD22 splicing variants (e.g., exon 12 deletion) |